VISTAGEN THERAPEUTICS, INC.
Income Statement
| Line Item | FY2017 | FY2016 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|
| Revenue | $1.3M | $0 | $200.4K | $1.3M | $2.1M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $5.2M | $3.9M | $3.4M | $5.4M | $3.7M |
| SG&A Expense | $6.3M | $13.9M | $3.6M | $5.0M | $5.0M |
| Operating Income | $-10.2M | $-17.9M | $-6.8M | $-9.0M | $-6.6M |
| Operating Margin | -819.9% | — | -3,389.8% | -673.8% | -317.0% |
| Interest Expense | $4.6K | $770.8K | $-920.7K | $-1.9M | $3.1M |
| Pretax Income | $-10.3M | $-47.2M | $-12.9M | $-12.2M | $-9.5M |
| Income Tax Expense | $2.4K | $2.3K | $3.7K | $1.6K | $1.6K |
| Net Income | $-10.3M | $-47.2M | $-12.9M | $-12.2M | $-9.5M |
| Net Margin | -820.4% | — | -6,430.5% | -909.7% | -457.9% |
| EPS (Basic) | $-0.51 | $-9.69 | $-0.42 | — | — |
| EPS (Diluted) | $-0.51 | $-9.69 | $-0.42 | $-0.28 | $-0.20 |
| Shares Outstanding (Basic) | 27.9M | 5.3M | 54.3M | — | — |
| Shares Outstanding (Diluted) | 27.9M | 5.3M | 54.3M | 44.2M | 47.2M |
| Dividends Per Share | — | — | — | — | — |